6/24/2008

GTC Biotherapeutics has entered into a deal worth up to $257 million with Ovation Pharmaceuticals to develop and market ATryn, an experimental treatment for hereditary anti-thrombin deficiency, in the U.S. GTC could receive up to $9 million in milestone payments upon approval of the drug, which has obtained orphan designation and fast-track status from the FDA.

Full Story:
Forbes, Reuters

Related Summaries